Company intelligence / Profile preview
DevaCell
San Diego, California, United Statesdevacell.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Preclinical
01
Overview
DevaCell is developing a pipeline of synthetic vector-based immunotherapeutics using its ONCoat™ platform. The lead program focuses on systemically delivered oncolytic virus therapies designed to activate and enhance the immune response against cancer. No clinical results have been published yet; programs appear to be preclinical.
- Therapeutic areas
- OncologyOther
- Modalities
- Synthetic vectorsOncolytic virusesImmunotherapeuticsGene therapy/gene editing platforms
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on DevaCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DevaCell.